Outcome of various regimes of maintenance therapy of lupus Nephritis. An observational study
Abstract
Aim: To study the outcome of lupus nephritis with various maintenance regimes.
Materials and Methods: An observational study, where lupus nephritis patients were followed quarterly, over a period of 2 years on maintenance therapy. Primary endpoint of complete response and secondary end point of partial response were compared in different treatment arms and subjected to the statistical analysis.
Results: More than 50% (26) patients achieved the primary end point of complete response and over 28% (15) achieved secondary end point of partial response. CR was seen in 40% of patients on MMF, 75% of patients on azathioprine arm and 42.5% of patients in CYC arm.
Clinical significance: Outcome was slightly better in patients receiving azathioprine, however the difference didn’t reach statistical significance.
Downloads
References
2. Hanly JG, O'Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2016 Feb. 55 (2):252-62
3. Galindo-Izquierdo M, Rodriguez-Almaraz E, Pego-Reigosa JM, et al. Characterization of Patients With Lupus Nephritis Included in a Large Cohort From the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER). Medicine (Baltimore). 2016 Mar. 95 (9):e2891.
4. Lewis, Edmund J.; Schwartz, Melvin M. (2010-11-04). Lupus Nephritis. OUP Oxford. pp. 174–177. ISBN 9780199568055.
5. Tak-Mao Chan, Kai-Chung Tse, Colin Siu-On Tang, Mo-Yin Mok, Fu-Keung Li and ; for the Hong Kong Nephrology Study Group JASN April 2005, 16 (4) 1076-1084; DOI: https://doi.org/10.1681/ASN.2004080686.
6. Henderson LK, Masson P, Craig JC, et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2013; 61:74.
7. Henderson L, Masson P, Craig JC, et al. Treatment for lupus nephritis. Cochrane Database Syst Rev 2012; 12:CD002922.
8. Tamirou F, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Fiehn C, Ayala Guttierez Mdel M, Gilboe IM, Tektonidou M, Blockmans D, Ravelingien I, le Guern V, Depresseux G, Guillevin L, Cervera R, Houssiau FA, MAINTAIN Nephritis Trial Group.
9. Gulizar Manga Sahin, SevgiSahin, SafakKiziltas, SevalMasatlioglu, FusunOguz, HulyaErgin Renal failure 30 (9), 865-869, 2008.
10. Kaballo Babikir G, Ahmed Ahmed Elias, Nur Musa Mohammed, Khalid Ismail Osman, Abu-Aisha Hasan Mycophenolate mofetil versus azathioprine for maintenance treatment of lupus nephritis.
11. Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365:1886.
12. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350:971.
13. Contreras G, Tozman E, Nahar N, Metz D. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus. 2005;14 Suppl 1:s33-8. doi: 10.1191/0961203305lu2115oa. PMID: 15803929.
14. Feng L, Deng J, Huo DM, Wu QY, Liao YH. Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: a meta-analysis. Nephrology (Carlton). 2013 Feb;18(2):104-10. doi: 10.1111/nep.12006. PMID: 23113811.
15. Ginzler EM, Dooley MA, Aranow C, et al.: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis, N Engl J Med 353:2219–2228, 2005.
16. Mok CC, Lau CS, Wong RW: Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy, Arthritis Rheum 41:831–837, 1998.
This work is licensed under a Creative Commons Attribution 4.0 International License.
